Veru Inc (DE:FMW0)
NASDAQ:FMW0
FMW0 Stock Chart & Stats
€3.44
--
Market closed
€3.44
--
Day’s Range― - ―
52-Week Range€3.09 - €5.83
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€32.49M
Enterprise Value€13.28M
Total Cash (Recent Filing)€30.76M
Total Debt (Recent Filing)€2.83M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding16,050,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.52Price Target Upside525.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Statistically Strong Phase IIb Functional Efficacy (enobosarm 3 Mg)A robust, statistically significant functional benefit at the 3 mg dose demonstrates the drug candidate can preserve lean mass and physical function when paired with GLP‑1 therapy. That structural efficacy supports differentiated label claims and improves long‑term commercialization and partnering prospects.
Pivotal‑feeding Phase IIb 'plateau' Study Initiated And EnrollingLaunching a ~200‑patient randomized plateau study creates a clear regulatory and clinical path with a near‑term, protocolized interim readout. This reduces binary development risk, enables data‑driven partnering or financing decisions, and materially de‑risks the program over the coming 6–12 months.
Improved Cash Position And Relatively Low LeverageMaterial equity proceeds and a $27.6M cash balance, combined with modest debt, extend runway through the planned interim analysis and provide flexibility. Lower leverage reduces near‑term solvency risk and gives management time to secure partnerships or non‑dilutive funding tied to clinical milestones.
Bears Say
Minimal Revenue And Persistent Cash BurnNear‑zero product revenue and sustained operating cash outflows mean R&D depends on external funding. Persistent burn erodes equity and increases the likelihood of future dilutive financings, constraining long‑term capital allocation and making sustained development contingent on clinical success.
Runway Contingent On A Single Interim MilestoneRelying on one interim readout to bridge financing creates execution risk: a negative result or delay could force urgent dilutive capital raises, strategic compromises, or program pauses. This dependency materially increases financing and operational risk over the next 6–12 months.
Regulatory And Competitive Complexity With GLP‑1 LandscapePotential need for agent‑specific trials, alternative endpoints, or additional BMD/function studies increases development time and cost. Combined with entrenched GLP‑1 leaders, this structural complexity raises commercialization barriers and could require multiple, costly studies to secure broad labeling.
Veru News
FMW0 FAQ
What was Veru Inc’s price range in the past 12 months?
Veru Inc lowest stock price was €3.09 and its highest was €5.83 in the past 12 months.
What is Veru Inc’s market cap?
Veru Inc’s market cap is €32.49M.
When is Veru Inc’s upcoming earnings report date?
Veru Inc’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Veru Inc’s earnings last quarter?
Veru Inc released its earnings results on May 13, 2026. The company reported -€0.112 earnings per share for the quarter, beating the consensus estimate of -€0.245 by €0.133.
Is Veru Inc overvalued?
According to Wall Street analysts Veru Inc’s price is currently Undervalued.
Does Veru Inc pay dividends?
Veru Inc does not currently pay dividends.
What is Veru Inc’s EPS estimate?
Veru Inc’s EPS estimate is -0.27.
How many shares outstanding does Veru Inc have?
Veru Inc has 16,050,320 shares outstanding.
What happened to Veru Inc’s price movement after its last earnings report?
Veru Inc reported an EPS of -€0.112 in its last earnings report, beating expectations of -€0.245. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Veru Inc?
Currently, no hedge funds are holding shares in DE:FMW0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veru Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.49%
12-Months-Change
Fundamentals
Return on Equity
-53.43%
Trailing 12-Months
Asset Growth
31.86%
Trailing 12-Months
Company Description
Veru Inc
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
FMW0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported meaningful clinical progress (positive Phase IIb functional results, active enrollment in a pivotal-feeding Phase IIb plateau study with interim readout expected Q1 2027) and materially improved near-term liquidity and expense trends. At the same time, Veru remains unprofitable, faces label and regulatory complexity (possible need for agent-specific studies or function/BMD endpoints), stiff competition from established GLP-1 players, and dependence on nonrecurring gains and an interim milestone for runway. On balance, the progress on clinical endpoints, the clear regulatory strategy contingencies, and improved cash position outweigh the operational and regulatory risks discussed.View all DE:FMW0 earnings summariesFMW0 Stock 12 Month Forecast
Average Price Target
€21.52
▲(525.65% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Cue Biopharma
―
Inmune Bio
―
Celularity
―
Jupiter Neurosciences, Inc.
―